These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28630381)

  • 1. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
    Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.
    Sadri-Ardalani F; Shabani M; Amiri MM; Bahadori M; Emami S; Sarrafzadeh AR; Noutash-Haghighat F; Jeddi-Tehrani M; Shokri F
    Tumour Biol; 2016 Jan; 37(1):1217-27. PubMed ID: 26282003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
    Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor.
    Kazemi T; Tahmasebi F; Bayat AA; Mohajer N; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
    Hybridoma (Larchmt); 2011 Aug; 30(4):347-53. PubMed ID: 21851234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2.
    Sarina N; Abeldenov S; Turgimbayeva A; Zhylkibayev A; Ramankulov Y; Khassenov B; Eskendirova S
    Hum Antibodies; 2018 Feb; 26(2):103-111. PubMed ID: 29036807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.
    Dimitriadis A; Gontinou C; Baxevanis CN; Mamalaki A
    BMC Cancer; 2009 Oct; 9():386. PubMed ID: 19878568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with HER2 extracellular subdomain proteins induces cellular response and tumor growth inhibition in mice.
    Ahmadi M; Sadri-Ardalani F; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Immunotherapy; 2018 Mar; 10(6):511-524. PubMed ID: 29562854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model.
    Ghaedi M; Golsaz-Shirazi F; Bahadori T; Khoshnoodi J; Mortezagholi S; Jeddi-Tehrani M; Amiri MM; Shokri F
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2437-2450. PubMed ID: 35737089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preparation and characterization of specific monoclonal antibodies against HER2].
    Liu HQ; Wang DM; Qu H; Shi L; Huang LH; Feng CL; Zhang LY; Zhu WB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 May; 26(5):456-8. PubMed ID: 20423652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Characterization of the Extracellular Domain of Human HER2 from Escherichia Coli, and Production of Polyclonal Antibodies Against the Recombinant Proteins.
    Sun Y; Feng X; Qu J; Han W; Liu Z; Li X; Zou M; Zhen Y; Zhu J
    Appl Biochem Biotechnol; 2015 Jun; 176(4):1029-43. PubMed ID: 25906688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of new HER2 monoclonal antibodies.
    Vasconcellos FA; Aleixo PB; Stone SC; Conceição FR; Dellagostin OA; Aleixo JA
    Acta Histochem; 2013 Apr; 115(3):240-4. PubMed ID: 22901624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori T; Golara M; Hassannia H; Khosravi Eghbal R; Khoshnoodi J; Judaki MA; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2017 Nov; 18(11):3103-3110. PubMed ID: 29172286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and characterization of a new chimeric antibody against HER2.
    Amiri MM; Jeddi-Tehrani M; Kazemi T; Bahadori M; Maddah M; Hojjat-Farsangi M; Khoshnoodi J; Rabbani H; Shokri F
    Immunotherapy; 2013 Jul; 5(7):703-15. PubMed ID: 23829622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
    Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.